Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer.

Cancer research communications - 1 Jun 2026

Serrano-Serrano Martha Liliana, Godfried Sie Christina, Bechter Oliver, Pretelli Giulia, Vieito María, Fontana Elisa, Han Catherine H, Castañón Álvarez Eduardo, Matos Ignacio, Pinato David J, Moreno Irene, Eefsen Rikke L, Plummer Ruth, Dummer Reinhard, Prenen Hans, Sutton Joseph, Cinato Elisa, Schnetzler Gabriel, Keshelava Nino, Roller Andreas

Abstract excerpt

The serine-threonine protein kinase B-RAF (BRAF) V600 mutation confers a poor prognosis in metastatic colorectal cancer (mCRC). Mosperafenib is a novel, paradox-breaking BRAF inhibitor (BRAFi). In this analysis of a phase I study (ISRCTN13713551), we evaluated circulating tumor DNA (ctDNA) as a prognostic and predictive biomarker for mosperafenib monotherapy in BRAF V600-mutant mCRC. We analyzed 49...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Colorectal Neoplasms

Share to Neoplasm Metastasis

Share to Prognosis

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 42127914
DOI: 10.1158/2767-9764.CRC-26-0196
PMCID: PMC13276731

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer.PMID 42127914Read ↗

Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis.Semantic proximity Read ↗

Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment.Semantic proximity Read ↗

Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumorsSemantic proximity Read ↗

Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study.Semantic proximity Read ↗

Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic ResponseSemantic proximity Read ↗

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA.Semantic proximity Read ↗

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.Semantic proximity Read ↗

Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma.Semantic proximity Read ↗

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.